Skip to product information
1 of 1

PE-Cy7 Mouse Anti-Human CD152 Antibody (BNI3)

PE-Cy7 Mouse Anti-Human CD152 Antibody (BNI3)

Catalog Number: S0B8229 Application: ICFCM Reactivity: Hu Conjugation: PE-Cy7 Brand: Starter
Price:
Regular price $413 USD
Regular price Sale price $413 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Synonyms Cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4); CTLA4
Location Cell membrane
Accession P16410
Clone Number BNI3
Antibody Type Mouse mAb
Isotype IgG2a,k
Application ICFCM
Reactivity Hu
Purification Protein A
Concentration 0.2 mg/ml
Conjugation PE-Cy7
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.3% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
ICFCM 1.25μl per million cells in 100μl volume Hu

Background

CD152 is a 223-amino-acid transmembrane glycoprotein receptor expressed mainly on activated CD4+ and CD8+ T cells that functions as a critical negative regulator of immune responses by out-competing CD28 for binding to the costimulatory ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, thereby transducing inhibitory signals that attenuate T-cell proliferation, cytokine production, and cell cycle progression; the protein’s signal peptide is cleaved to yield a disulfide-linked homodimer whose extracellular Ig-like V-type domain mediates high-avidity ligand engagement, while its cytoplasmic tail contains a tyrosine-based motif that recruits phosphatases such as SHP-2 and PP2A to propagate inhibitory cascades, and genetic polymorphisms or therapeutic blockade of CD152 (e.g., the monoclonal antibody ipilimumab) can enhance antitumor immunity but also precipitate autoimmune toxicities, underscoring its pivotal role in maintaining immune homeostasis.

Picture

FC

Flow cytometric analysis of CD152 expression in activated human PBMC (human peripheral blood mononuclear cell). PHA-activated (2 days) human PBMC were fixed with 4% PFA and permeabilization with the 0.1% Tween and then were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 antibody and either PE-Cy7 Mouse IgG2a, κ Isotype Control (right panel) or SDT PE-Cy7 Mouse Anti-Human CD152 Antibody at 1.25 μl/test (right panel) treated with True-Stain Monocyte Blocker™. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software